An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of the ATR Inhibitor M1774 in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors.

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT05396833

Study #:
STUDY00160647

Start Date:
Jan 10, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05396833

View Complete Trial Details & Eligibility at ClinicalTrials.gov